Lenalidomide Sandoz 7.5 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4 E3 ubiquitin ligase complex, leading to the degradation of transcription factors Ikaros and Aiolos. This action modifies the immune response, inhibits new blood‑vessel formation, and triggers apoptosis of malignant plasma cells, providing anti‑myeloma activity.

The specific dose of Lenalidomide Sandoz 7.5 mg is determined by the treating physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Clinicians tailor the regimen to achieve optimal efficacy while monitoring safety, and patients should follow the prescriber’s instructions exactly.

Lenalidomide is classified as Pregnancy Category X, meaning it is contraindicated in pregnant women because it can cause fetal harm. Women of child‑bearing potential must use effective contraception during treatment and for a defined period after the last dose. Breastfeeding is not recommended while taking lenalidomide.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and assistance with import documentation.

Lenalidomide belongs to the immunomodulatory drug (IMiD) class, sharing a mechanism with thalidomide and pomalidomide. Compared with thalidomide, lenalidomide generally offers a more favorable side‑effect profile, especially regarding neuropathy, while providing comparable anti‑myeloma efficacy. Pomalidomide may be used after lenalidomide failure, offering an additional option for resistant disease.

Store the capsules at ambient temperature, preferably below 25 °C (77 °F). Keep them in the original blister pack or container to protect from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

Lenalidomide is taken orally as a hard capsule with a full glass of water. It may be taken with or without food, but patients should follow the prescriber’s guidance regarding timing relative to meals. Capsules should be swallowed whole and not opened, crushed, or chewed.

Serious risks include severe neutropenia and thrombocytopenia, which can lead to infection or bleeding; deep‑vein thrombosis or pulmonary embolism; life‑threatening skin reactions such as Stevens‑Johnson syndrome; and the potential development of secondary primary malignancies. Patients should report any signs of infection, unusual bruising, swelling of limbs, or severe rash promptly.

Lenalidomide should not be used by pregnant women or women who could become pregnant without effective contraception. It is also contraindicated in patients with known hypersensitivity to lenalidomide or any component of the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled infections, or a history of thromboembolic events.